Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Comstock Resources (NYSE:CRK): Capital Discipline Matters Beyond Commodity Prices

Comstock Resources (NYSE:CRK) is a leveraged bet on the Haynesville, and in a gas market that has been weak, the swingFactorfor the stock is less theCommodityprice on any given day than how disciplined the company is with capital. The second quarter of 2026 illustrates …

Nitish Kishor | 18 September 2026

Corsa Coal (OTC:CRSXQ) Is a Bankruptcy Story Before It's a Coal Story

For a company like Corsa Coal (OTC:CRSXQ), any discussion of coal prices has to begin with a more basic fact: theBusinessentered formalInsolvencyproceedings. The ticker itself carries the tell, the 'Q' appended to CRSXQ is the market's shorthand for a company in bankruptcy. So while …

Nitish Kishor | 18 September 2026

Core Laboratories (NYSE:CLB) Puts Earnings Quality Ahead of Sector Sentiment

Core Laboratories (NYSE:CLB) operates in a corner of the energy sector that trades heavily on sentiment: oilfield services, where share prices often swing with the oil price and the drilling mood rather than with the underlying business. Core's second-quarter 2026 results argue for looking …

Nitish Kishor | 18 September 2026

AleAnna (NASDAQ:ANNA) Puts Italy's Domestic Gas Opportunity in Focus

AleAnna (NASDAQ:ANNA) answers its own headline: it is an energy company built around Italy's domestic natural-gas opportunity, and its recent results show why that opportunity matters. Italy imports a large share of its gas, so locally produced volumes can be sold into a market …

Nitish Kishor | 18 September 2026

Barclays Downgrades Cellectis (NASDAQ: CLLS) Two Notches to Underweight and Cuts Price Target to $1.30 From $9.00

1. Rating Moves Straight From Overweight to Underweight:The two-notch revision skips the neutral position entirely, signalling a wholesale change of view rather than a marginal adjustment.

Nitish Kishor | 18 September 2026

OS Therapies (NYSE: OSTX) Reaches Alignment With European Regulators on Adaptive Phase 3 Design for OST-HER2 in Resected Pulmonary Metastatic Osteosarcoma

1. European Regulatory Consensus Enables a 4Q 2026 Trial Start:Agreement on the pivotal design removes a category of procedural risk before enrolment begins.

Nitish Kishor | 18 September 2026

InMed Pharmaceuticals (NASDAQ: INM) Sees ADAR1 Capital Management Buy About $117,700 of Stock, Lifting Indirect Holding to 892,101 Shares

1. Open-Market Purchases Totalled Roughly $117,700:Buying executed at prevailing prices carries a different signal than participation in a negotiated financing.

Nitish Kishor | 18 September 2026

Nuvation Bio (NYSE: NUVB) Wins FDA Approval of IBTROZI sNDA Adding 49.7-Month Median Duration of Response Four Months Ahead of PDUFA Date

1. FDA Cleared the Label Update Four Months Before the PDUFA Target Date:Early action generally indicates a review without substantive outstanding questions.

Nitish Kishor | 18 September 2026

Biotech Clinical and Regulatory Roundup: Longeveron (NASDAQ: LGVN) Endpoint Miss, Nuvation Bio (NYSE: NUVB) Label Win, OS Therapies (NYSE: OSTX) EU Alignment and Tiziana (NASDAQ: TLSA) MS Collaboration

1. One Clear Failure and One Clear Approval Framed the Period:Longeveron (NASDAQ: LGVN) missed a Phase 2b primary endpoint while Nuvation Bio (NYSE: NUVB) secured an early FDA label update.

Nitish Kishor | 18 September 2026

Biotech Capital Markets Roundup: Aethlon Medical (NASDAQ: AEMD) Reverse Merger, MediciNova (NASDAQ: MNOV) Buy Initiation, Cellectis (NASDAQ: CLLS) Downgrade and InMed (NASDAQ: INM) Institutional Buying

1. A $180 Million Financing Anchored the Largest Structural Transaction:Aethlon Medical (NASDAQ: AEMD) agreed an all-stockMergerwith North Immunology creating NRTX at a $346.5 million pro formaEquityvalue.

Nitish Kishor | 18 September 2026
Support

Hi! How can we help you today?

Loading…